{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T20:27:50Z","timestamp":1767990470340,"version":"3.49.0"},"reference-count":11,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sparsentan is a single\u2010molecule dual antagonist of the endothelin type A receptor and angiotensin II type 1 receptor under investigation for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. Dapagliflozin, a sodium\u2010glucose cotransporter 2 inhibitor, has recently been indicated in chronic kidney disease. Sparsentan may be considered for concomitant use with dapagliflozin. The purpose of this open\u2010label, 1\u2010sequence crossover study was to determine whether drug\u2013drug interactions between sparsentan and dapagliflozin affect dapagliflozin pharmacokinetics (PK). In addition, exposure to the inactive metabolite of dapagliflozin, dapagliflozin\u20103\u2010O\u2010glucuronide, was used to evaluate the effect of sparsentan on the primary metabolizing enzyme of dapagliflozin, uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase 1A9. The study included 22 healthy adults treated with 10\u00a0mg of dapagliflozin on day 1, and 800\u00a0mg\/day of sparsentan on days 5\u201314, with a 10\u2010mg dose of dapagliflozin coadministered on day 11. PK samples were taken for dapagliflozin, dapagliflozin\u20103\u2010O\u2010glucuronide, and sparsentan before and after treatment throughout the study. Steady\u2010state concentrations of sparsentan following daily dosing did not affect the PK of single\u2010dose dapagliflozin in healthy adults. Dapagliflozin\u20103\u2010O\u2010glucuronide PK suggests a minimal effect of sparsentan on metabolism of dapagliflozin by uridine 5\u2032\u2010diphospho\u2010glucuronosyltransferase 1A9. No deaths, serious adverse events, or unusual safety signals occurred. Results suggest dapagliflozin PK is not affected by sparsentan daily dosing.<\/jats:p>","DOI":"10.1002\/cpdd.1231","type":"journal-article","created":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T18:49:01Z","timestamp":1677610141000},"page":"535-541","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of Multiple Doses of Sparsentan on the Single\u2010Dose Pharmacokinetics of Dapagliflozin: An Open\u2010Label Drug\u2013Drug Interaction Study in Healthy Adults"],"prefix":"10.1002","volume":"12","author":[{"given":"Shang\u2010Chiung","family":"Chen","sequence":"first","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danlin","family":"Cai","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Winnett","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neeraj","family":"Verma","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila","family":"Preciado","sequence":"additional","affiliation":[{"name":"Travere Therapeutics, Inc.  San Diego CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00425.2015"},{"key":"e_1_2_8_3_1","first-page":"788A","article-title":"Anti hypertensive effects of sparsentan, a dual angiotensin II and endothelin type A receptor antagonist [abstract]","volume":"27","author":"Komers R","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2017.02.019"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018010091"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10071815"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfab335"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.03.033"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0104-3"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.22259\/2638-4981.0202003"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01434.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0517"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1231","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1231","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1231","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T02:31:11Z","timestamp":1692585071000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1002\/cpdd.1231"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1231","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"assertion":[{"value":"2022-10-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}